MARKET

PLSE

PLSE

Pulse
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.37
-0.08
-0.27%
Closed 16:42 03/02 EST
OPEN
29.58
PREV CLOSE
29.45
HIGH
30.19
LOW
28.83
VOLUME
176.16K
TURNOVER
--
52 WEEK HIGH
45.82
52 WEEK LOW
5.11
MARKET CAP
765.44M
P/E (TTM)
-13.6630
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Wall Street Analysts Are Bullish on Top Healthcare Picks
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pulse Biosciences (PLSE), Revance Therapeutics (RVNC) and
SmarterAnalyst · 02/24 08:21
Analysts Are Bullish on Top Healthcare Stocks: Pulse Biosciences (PLSE), Revance Therapeutics (RVNC)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pulse Biosciences (PLSE), Revance Therapeutics (RVNC) and
SmarterAnalyst · 02/24 06:54
8-K: Pulse Biosciences, Inc.
(EDGAR Online via COMTEX) -- plse-20210222x8k false000162510100016251012021-02-222021-02-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C....
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/23 05:24
DJ Pulse Biosciences, Inc. CEO Darrin Uecker on Q4 2020 Results -- Earnings Call Transcript >PLSE
Dow Jones · 02/23 03:08
Pulse Biosciences EPS misses by $0.09
Pulse Biosciences (PLSE): Q4 GAAP EPS of -$0.54 misses by $0.09.Cash, equivalents and investments totaled $20.5M as of Dec. 31, 2020.Press Release
Seekingalpha · 02/22 21:38
Pulse Biosciences Q4 EPS $(0.54) Misses $(0.45) Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.45) by 20 percent. This is a 18.18 percent increase over losses of $(0.66) per share from
Benzinga · 02/22 21:21
BRIEF-Pulse Biosciences Reports Q4 And Full Year 2020 Financial Results
reuters.com · 02/22 21:10
Pulse Biosciences 4Q Loss $13.8M >PLSE
Pulse Biosciences 4Q Loss $13.8M >PLSE
Dow Jones · 02/22 21:09
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PLSE. Analyze the recent business situations of Pulse through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PLSE stock price target is 46.00 with a high estimate of 46.00 and a low estimate of 46.00.
EPS
Institutional Holdings
Institutions: 72
Institutional Holdings: 3.12M
% Owned: 11.98%
Shares Outstanding: 26.06M
TypeInstitutionsShares
Increased
18
92.61K
New
10
120.06K
Decreased
18
55.70K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.55%
Healthcare Equipment & Supplies
-0.56%
Key Executives
Chairman/Independent Director
Robert Duggan
President/Chief Executive Officer/Director
Darrin Uecker
Chief Financial Officer/Executive Vice President - Finance/Treasurer/Secretary
Sandra Gardiner
Executive Vice President/General Manager
Edward Ebbers
Independent Director
Kenneth Clark
Independent Director
Mitchell Levinson
Independent Director
Manmeet Soni
Independent Director
Mahkam Zanganeh
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About PLSE
Pulse Biosciences, Inc. is a clinical-stage medical device company using a platform technology called Nano-Pulse stimulating (NPS). NPS is a non-thermal, precise, focal drug-free electroceutical treatment technology that initiates cell death within treated tissue. NPS provides treatment in a range of immuno-oncology, dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret's esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing PulseTx system (PulseTx), a system for the delivery of NPS treatments. The PulseTx system delivers NPS pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.

Webull offers kinds of Pulse Biosciences Inc stock information, including NASDAQ:PLSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLSE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLSE stock methods without spending real money on the virtual paper trading platform.